What is ketamine?
Ketamine is an anesthetic. It is a preferred choice in operating rooms and clinical settings today due to its excellent safety profile. First approved by the US Food & Drug Administration in 1970, Ketamine was originally brought to market as a safer alternative to existing anesthetics.
Ketamine as an antidepressant.
At the start of the 21st century, ketamine was found to be remarkably effective as an antidepressant when administered in low doses.
Unlike traditional antidepressants which can take weeks to make an impact, Ketamine can rapidly reduce depressive symptoms within two hours of administration, and this relief can be sustained for up to two weeksfollowing just a single dose.
Ketamine triggers neuroplasticity (a state when your brain can more easily learn, change and adapt), allowing the brain to make new connectionsand disconnect from old patterns of thinking, which contribute to mental health symptoms. This creates a temporary window for establishing new habits, thought patterns, and perceptions.
Ketamine has been studied as an anaesthetic for over 50 years.
As an antidepressant, ketamine has been proven to provide rapid and sustained relief.
Ketamine is approved for therapeutic use in the US and Canada.
Ketamine takes effect in minutes, and only lasts for about 45-90 minutes.
Dosage is personalized throughout treatment, customized just for you.
Frequently asked questions.
Is ketamine a psychedelic?
Is ketamine safe?
How is ketamine taken at Field Trip?
How does ketamine feel?
Generally, clients report...
Are there ketamine side effects?
The way ketamine is used can change its effectiveness.
While ketamine alone can be used as an antidepressant, there is mounting evidence suggesting that ketamine, when administered with psychotherapy, has longer lasting improvements in depression and anxiety severity.4-6Learn More
1. Zarate et al (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
3. Nutt, D. J., King, L.A., & Phillips, L. D. (2010), Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(9752). 1558-1565. https://doi.org/10.1016/s0140-6736(10)61462-6
4. Dore J. et al (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy.
5. aan het Rot, M. et al (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression